10. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review:
mesenchymal stem cells: their phenotype, differentiation capacity, immunological
features, and potential for homing. Stem Cells. 2007; 25(11): 2739-2749.
11. Bachrach E, Perez AL, Choi YH, et al. Muscle engraftment of myogenic
progenitor cells following intraarterial transplantation. Muscle Nerve. 2006;
34(1): 44-52.
12. Bailo M, Soncini M, Vertua E, et al. Engraftment potential of human
amnion and chorion cells derived from term placenta. Transplantation. 2004;
78(10): 1439-1448.
13. Pelatti MV, Gomes JP, Vieira NM, et al. Transplantation of human
adipose mesenchymal stem cells in non-immunosuppressed GRMD dogs is a safe
procedure. Stem Cell Rev. 2016; 12(4): 448-53. doi: 10.1007/s12015-016-9659-3.
14. Vieira NM, Valadares M, Zucconi E, et al. Human adipose-derived
mesenchymal stromal cells injected systemically into GRMD dogs without
immunosuppression are able to reach the host muscle and express human
dystrophin. Cell Transplant. 2012; 21(7): 1407-1417. doi: 10.3727/096368911X.
15. Rodriguez AM, Pisani D, Dechesne CA, et al. Transplantation of a
multipotent cell population from human adipose tissue induces dystrophin
expression in the immunocompetent mdx mouse. J Exp Med. 2005; 201(9): 1397-
1405. doi: 10.1084/jem.20042224.
16. Ichim TE, Alexandrescu DT, Solano F, et al. Mesenchymal stem cells as
anti-inflammatories: implications for treatment of Duchenne muscular dystrophy.
Cellular Immunol. 2010; 260(2): 75-82. doi: 10.1016/j.cellimm.2009.10.006.
17. Acibadem University. Efficacy of Umbilical Cord Mesenchymal Stem
Cells in Duchenne Muscular Dystrophy. In: ClinicalTrials.gov [Internet].
Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016Jul].
Available
from:
https://clinicaltrials.gov/ct2/show/NCT02285673
NLM
Identifier: NCT02285673.
18. Allogeneic human umbilical cord mesenchymal stem cells for a single
male patient with Duchenne muscular dystrophy (DMD). ClinicalTrials.gov
NCT02235844.
